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Objective: Arachidonate 12-lipoxygenase (ALOX12) is a member of the lipoxygenase superfamily, which catalyzes the
incorporation of molecular oxygen into polyunsaturated fatty acids. The products of ALOX12 reactions serve as endogenous
ligands for peroxisome proliferator-activated receptor g (PPARG). The activation of the PPARG pathway in marrow-derived
mesenchymal progenitors stimulates adipogenesis and inhibits osteoblastogenesis. Our objective was to determine whether
polymorphisms in the ALOX12 gene were associated with variations in peak bone mineral density (BMD) and obesity
phenotypes in young Chinese men.
Methods: All six tagging single-nucleotide polymorphisms (SNPs) in the ALOX12 gene were genotyped in a total of 1215
subjects from 400 Chinese nuclear families by allele-specific polymerase chain reaction. The BMD at the lumbar spine and hip,
total fat mass (TFM) and total lean mass (TLM) were measured using dual-energy X-ray absorptiometry. The pairwise linkage
disequilibrium among SNPs was measured, and the haplotype blocks were inferred. Both the individual SNP markers and the
haplotypes were tested for an association with the peak BMD, body mass index, TFM, TLM and percentage fat mass (PFM) using
the quantitative transmission disequilibrium test (QTDT).
Results: Using the QTDT, significant within-family association was found between the rs2073438 polymorphism in the ALOX12
gene and the TFM and PFM (P¼0.007 and 0.012, respectively). Haplotype analyses were combined with our individual SNP
results and remained significant even after correction for multiple testing. However, we failed to find significant within-family
associations between ALOX12 SNPs and the BMD at any bone site in young Chinese men.
Conclusions: Our present results suggest that the rs2073438 polymorphism of ALOX12 contributes to the variation of obesity
phenotypes in young Chinese men, although we failed to replicate the association with the peak BMD variation in this sample.
Further independent studies are needed to confirm our findings.
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Introduction
It was once thought that osteoporosis and obesity were
unrelated,
1 but there is accumulating evidence confirming
their association in recent decades. Weight is a major
determinant of bone mineral density (BMD); subjects who
are overweight or obese have a relatively higher BMD, and
weight loss is associated with an increased risk of osteo-
porotic fracture.
2,3 With aging, bone mass is reduced, whereas
adipocyte volume in bone marrow is increased.
4 Both
osteoporosis and obesity have strong genetic components,
as the heritability of obesity is estimated at 40–60%,
5 and
60–80% of the variance in BMD is genetically determined.
6 In
addition, both osteoblasts and adipocytes are derived from
mesenchymal stem cells. Extensive data have shown that
both adipogenesis and osteogenesis share multiple common
genetic factors and signaling pathways, such as vitamin D
receptor, peroxisome proliferator-activated receptor g (PPARG),
transforming growth factor-b and Wnt pathways.
1,7,8.M e a n -
while, adipocytes can secrete estrogen, leptin and inflamma-
tory cytokines to influence bone metabolism.
9 Therefore,
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www.nature.com/ijoexploring the interface between bone and fat at the molecular
and genetic levels may improve our understanding of
osteoporosis and obesity, which may lead to new interventions
and treatments.
Body weight is determined mostly by fat, muscle and bone
mass. Body composition assessment by dual-energy X-ray
absorptiometry (DXA) is a readily accessible, inexpensive
and non-invasive method. DXA detects total body mineral
mass, total fat mass (TFM) and total lean mass (TLM). The
relationships between bone mass and TFM and TLM have
been examined, although the results are controversial.
10–12
Studies have also shown several genomic regions that
influence both obesity and osteoporosis.
13,14 Although
various candidate genes have been identified that may
contribute to BMD, far less is known about genes affecting
obesity phenotypes such as BMI, TLM and TFM.
Recently, Klein et al.
15 suggested that mouse arachidonate
15-lipoxygenase (ALOX15) could negatively regulate peak
bone mass. Compared with control mice, ALOX15 knockout
mice have a higher BMD, and pharmacologic inhibitors of
ALOX15 improve the BMD and bone strength in a model
of osteoporosis. It has also been reported that overexpression
of human ALOX15 in transgenic rabbits protects against
bone loss.
16 However, based on the products of their
lipoxygenase reactions, mouse ALOX15 is functionally more
similar to human ALOX12.
17,18 Therefore, human ALOX12
might represent a strong candidate gene for susceptibility to
osteoporosis. In fact, a positive correlation between ALOX12
gene polymorphisms and BMD in human beings has been
established by previous studies,
19–21 although all the studies
were limited to Caucasian samples. So far, no such data have
been reported for an Asian population. Moreover, most
previous studies of candidate genes have been performed in
women, with only one study focusing on men.
The human ALOX12 gene is composed of 14 exons and 13
introns, mapping to chromosome 17p13, a region that is
thought to be associated with body mass index (BMI) (http://
obesitygene.pbrc.edu). Furthermore, ALOX12 has an impor-
tant function in obesity-related complex phenotypes, inclu-
ding hypertension, diabetes, atherosclerosis and insulin
secretion.
22–24 However, the relationship between ALOX12
and obesity has never been studied. In this study, we
performed family-based-association analyses on all six
tagging single-nucleotide polymorphisms (SNPs) in the
ALXO12 gene using the quantitative transmission disequili-
brium test (QTDT) to determine whether SNPs and haplo-
types in ALXO12 were associated with peak BMD variations
and obesity-related phenotypes in a large sample of Chinese
males in nuclear families.
Materials and methods
Subjects
We recruited 1296 individuals from 427 Chinese nuclear
families with male offspring from 2004 to 2007. The average
family size was 3.03, as 402 and 25 families had 1 and
2 children, respectively. Every study subject completed a
questionnaire concerning age, sex, medical history, family
history, marital status, physical activity, alcohol use, diet
habits and smoking history. All male offspring were healthy.
The following criteria were used to exclude individuals from
the study: (1) serious effects from cerebrovascular disease;
(2) diabetes mellitus; (3) chronic renal disease; (4) serious
chronic liver disease or alcoholism; (5) significant chronic
lung disease; (6) corticosteroid therapy at pharmacologic
levels for 43 months; (7) treatment with anticonvulsant
therapy for 46 months; (8) evidence of other metabolic or
inherited bone diseases such as hyper- or hypoparathyroid-
ism, Paget’s disease of the bone, osteomalacia, osteogenesis
imperfecta or others; (9) rheumatoid arthritis or collagen
disease; (10) recent major gastrointestinal disease (within
the past year) such as peptic ulcer, malabsorption, chronic
ulcerative colitis, regional enteritis or any significant chronic
diarrhea state; (11) significant disease of any endocrine
organ that would affect bone mass; (12) hyperthyroidism
and (13) any neurological or musculoskeletal condition that
would be a non-genetic cause of low bone mass.
All study subjects belonged to the Chinese Han ethnic
group. All were residents of Shanghai City, located on the
mid-eastern coast of China. The study was approved by
the ethics committee of the Shanghai Jiao Tong University
Affiliated Sixth People’s Hospital. All subjects signed
informed consent documents before entering the study.
BMD and body composition measurements
The BMD of the lumbar spine 1–4, the left proximal femur
(including the femoral neck and the total hip), as well as
TFM and TLM were measured by DXA on a GE-LUNAR
Prodigy (Lunar Corp., Madison, WI, USA) in fan-beam mode.
All subjects were measured for BMD, and all sons were also
measured for TFM and TLM. The machine was calibrated
daily, and the coefficient of variability values of the DXA
measurements (which were obtained from 15 individuals
repeated three times) were 1.39% for the lumbar spine,
2.22% for the femoral neck and 0.70% for the total hip. The
coefficient of variabilities were 1.18 and 3.72% for TLM and
LFM, respectively. The long-term reproducibility of our DXA
data during the trial, based on weekly repeated phantom
measurements using standardized equipment, was 0.45%.
BMI is defined as body weight/height
2 (kgm
–2). The
percentage fat mass (PFM) is the ratio of TFM to body weight.
Genotyping
SNPs located within the ALOX12 gene were selected from
the NCBI LocusLink (http://Ncbi.nlm.nih.gov/LocusLink)
and HapMap (http://hapmap.org). Polymorphisms spanning
the ALOX12 gene were selected from the SNPs resource based
on the estimated pairwise linkage disequilibrium (LD), r
2,
between all common SNPs. The algorithm bins SNPs whose
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2 of 0.8, tagging SNPs are
selected from each bin to constitute a minimal set of highly
informative markers, whereas minimizing redundant data.
We selected SNPs on the basis of the following criteria:
(1) degree of heterozygosity (minor allele frequencies 40.10)
and (2) classification as tagging SNPs. In total, six SNPs in
the ALOX12 gene were selected: rs2073438, rs2292350,
rs312470, rs434473, rs1235805 and rs312462. The study
subjects were genotyped for all six SNPs using the TaqMan
allelic discrimination assay (Applied Biosystems, Foster City,
CA, USA), whereas primer and probe sequences were
optimized using the SNP assay-by-design service of Applied
Biosystems. Reactions were performed on the Mx3000P
Real-Time PCR System (STRATAGENE, La Jolla, CA, USA).
One allelic probe was labeled with FAM dye and the other
with HEX dye. Genomic DNA (20ng) was amplified on
96-well plates in the presence of a 1  TaqMan probe assay and
1  TaqMan Universal PCR Master Mix (Applied Biosystems).
LD and haplotype analyses
Haplotypes were constructed from the population genotype
data by the algorithm of Stephens using the Phase program,
version 2.0.2. Significant levels of LD between the markers
of this gene were assessed based on the observed haplotype
and allele frequencies using Haploview 3.2.
25 We examined
Lewontin’s D and LD coefficient r
2 between all pairs of
biallelic loci. The frequencies of genotypes and haplotypes
were calculated using the unrelated parents of nuclear
families.
Statistical analyses
The allele frequencies were estimated by gene counting.
Hardy–Weinberg equilibrium was tested by a w
2 goodness-
of-fit statistic. To ensure unrelated individual samples, only
genotype data from the parents of each nuclear family were
used in the statistical analysis. The heritability estimate was
performed using a linear regression of the parents’ mean
value and the offspring’s value of every phenotype (described
at http://www.heritability.com). The statistical power was
estimated with Piface software (version 1.65) (http://
www.math.uiowa.edu/~rlenth/Power/) on our current
sample size according to the minor allele frequency of
every genotype and the variation of the BMD and obesity
phenotypes. The QTDT program using the orthogonal model
was used to test for population stratification, linkage and
within-family association between SNPs and haplotypes and
BMD phenotypes, TLM, TFM and BMI. The QTDT software
package is available online (http://www.sph.umich.edu/csg/
abecasis/QTDT/). This method, as implemented in the QTDT
software,
26 extends the trio-based TDT to quantitative trait
data and uses genotype data from available siblings and
parents. As in our nuclear families, all of the children were
sons and the effects of parent phenotypes were excluded
in the QTDT, sex was not used as a covariate to adjust the
variations in the sons’ bone phenotypes. The raw BMD
values were adjusted by age, height and weight as covariates,
and BMI, TFM and TLM were adjusted by age as covariates.
As false-positive results might be generated in multiple tests,
which were used in this study, permutations (1000 simula-
tions) were performed to generate the empirical P-values
26,27
to assess the reliability of the results. The QTDT program
generates P-values for various tests through an asymptotic
w
2 distribution. Po0.05 was considered significant for all
analyses.
In unrelated sons, the differences in the BMD among the
genotype and haplotype groups were tested using general
linear model ANOVA (GLM-ANOVA) adjustments for the
confounding variables of age, height and weight. The
differences in the BMI, TFM and TLM among the genotype
and haplotype groups were performed using GLM-ANOVA
adjusted for age. To evaluate the associations of the TFM and
TLM with the BMD, we used Pearson’s correlation analyses to
examine the coefficient (r) and multiple linear regression
to estimate the relative contribution of the TFM and TLM to
the BMD at various sites in young men. Statistical analysis
was performed using SPSS, version 11.0 (SPSS, Chicago,
IL, USA).
Results
Basic characteristics of the study subjects
Of the males sampled from 427 nuclear families, 15
individuals could not be genotyped because of the poor
quality of the DNA sample, and 12 sons deviated from
Mendelian inheritance. Ultimately, there were 400 male
nuclear families composed of 1215 individuals in this study.
The basic characteristics of the study subjects are shown in
Table 1. As the effects of parent phenotypes were excluded in
the statistical analysis (both the QTDT and ANOVA), we only
obtained the TFM and TLM of sons in this study. Peak BMD
is thought to be under strong genetic control. In our
sample, the heritability estimates for the peak BMD in the
Table 1 Basic characteristics of the subjects (mean±s.d.)
Variables Father
(n¼400)
Mother
(n¼400)
Son
(n¼415)
Age (years) 61.1±7.1 58.4±6.3 30.4±6.1
Height (cm) 167.8±6.0 155.7±5.5 172.9±5.9
Weight (kg) 69.7±9.5 58.2±8.2 70.7±10.8
BMI (kgm
–2)2 5 . 2 ±2.7 24.0±3.1 24.2±3.2
Lumbar spine BMD (gcm
–2) 1.139±0.171 0.992±0.168 1.138±0.137
Femoral neck BMD (gcm
–2) 0.892±0.132 0.796±0.144 0.995±0.141
Total hip BMD (gcm
–2) 0.958±0.138 0.852±0.162 1.008±0.142
TFM (kg) FF 16.31±7.56
TLM (kg) FF 51.43±5.76
PFM (%) FF 21.89±7.17
Abbreviations: BMD, bone mineral density; BMI, body mass index;
PFM, percentage fat mass; TFM, total fat mass; TLM, total lean mass.
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0.693, respectively.
Relationship between the BMD and the TFM and TLM in
young men
As shown in Table 2, Pearson’s correlation analyses
confirmed that both the TFM and TLM were positively
correlated with the BMD, with correlations ranging from
0.198 to 0.508 for the lumbar spine, femoral neck and total
hip BMD. According to the Pearson’s coefficient (r), the
TLM was more strongly related to the BMD at a given site.
To determine the relative contributions of the TLM and
TFM to the BMD, we constructed multiple regression
models, which were simultaneously adjusted for age and
height. Both the TLM and TFM were positively correlated
with the BMD, whereas the TLM had a significantly greater
effect on the BMD than the TFM per kilogram of tissue mass
(Table 3).
SNP genotyping and LD
Six SNPs in the ALOX12 gene were genotyped; rs1235805
was excluded from further analysis because of the existence
of homologous gene sequences, and too many families failed
to pass the Mendelian inheritance check. The remaining five
SNPs had a minor allele frequency of at least 0.15 and were
in Hardy–Weinberg equilibrium (Table 4).
To gain insight into the pattern of LD between alleles
at polymorphic loci, pairwise disequilibria measures (D)
were calculated (Figure 1). We found that each of these SNPs
was in strong LD (D40.80), and one block with high LD
was identified. We inferred that 19 different haplotypes were
present in our population using a likelihood method based
on PHASE. The most common haplotype (AGAGG) had a
frequency of 31.8%, and four haplotypes (AGAGG, GAAAG,
Table 2 Pearson’s correlation coefficient (r) of the BMD with the TFM
and TLM
Variation Lumbar spine
BMD (gcm
–2)
Femoral neck
BMD (gcm
–2)
Total hip BMD
(gcm
–2)
TFM
(kg)
TLM
(kg)
Lumbar spine FFF F F
BMD (gcm
–2) FFF F F
Femoral neck 0.639 FF F F
BMD (gcm
–2) (0.000) FF F F
Total hip 0.719 0.922 FF F
BMD (gcm
–2) (0.000) (0.000) FF F
Total fat 0.243 0.198 0.242 FF
mass (kg) (0.000) (0.000) (0.000) FF
Total lean 0.389 0.470 0.508 0.367 F
mass (kg) (0.000) (0.000) (0.000) (0.000) F
Abbreviations: BMD, bone mineral density; TFM, total fat mass; TLM, total lean
mass. Statistical significance is indicated in parentheses with the relevant P-values.
Table 3 Multivariate regression analysis of the BMD against body
composition components
BMD Total lean mass Total fat mass
b R
2 b R
2
Lumbar spine 0.010** 0.149 0.005** 0.056
Femoral neck 0.012** 0.210 0.004** 0.051
Total hip 0.012** 0.249 0.005** 0.068
Abbreviations: BMD, bone mineral density; TFM, total fat mass; TLM, total
lean mass. Models were adjusted for age and height. **Po0.001.
Table 4 Information on the ALOX12 SNPs analyzed in this study
SNP Physical position Location and function Allele change HWE P-value MAF in European
a MAF in Asian
a MAF in this study
rs2073438 6840800 Intron 1 A4G 0.43 0.308 0.333 0.353
rs2292350 6842396 Intron 2 A4G 0.98 0.645 0.263 0.338
rs312470 6842903 Intron 4 A4G 0.57 0.045 0.256 0.159
rs434473 6845658 Exon 8 (Asn322Ser) A4G 0.44 0.467 0.444 0.494
rs312462 6854376 Exon 14 (Leu634Leu) G4A 0.24 0.133 0.111 0.151
Abbreviations: HWE, Hardy–Weinberg equilibrium; MAF, minor allele frequency; SNP, single-nucleotide polymorphism.
aAccording to public information available in
the dbSNP (http://www.ncbi.nlm.nih.gov) and the HapMap (http://www.Hapmap.org) databases.
Figure 1 LD patterns for the ALOX12 gene. The increasing degree of the
darkness of the cells from white to black represents the increasing strength of
the LD. The values in the cells are the pairwise degree of LD indicated by
D 100 when Do1.
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parents.
Association of the peak BMD and obesity phenotypes with SNPs
in nuclear families
ANOVA and QTDT analyses. Using 400 nuclear families has
a power of 480% to test a candidate gene as a QTL, which
can explain B10% of the variation in the BMD or obesity
phenotypes. We investigated the association of the SNP
genotypes with the BMD and obesity phenotypes using
ANOVA in 400 unrelated sons randomly selected from 415
sons. Two SNPs (rs2073438 and rs312462) showed significant
association with the TFM and PFM (Po0.05). The sons with
the AA genotype at rs2073438 had a higher adjusted TFM
(P¼0.001) and a higher PFM (P¼0.014) compared with the
GG genotype. This SNP contributed to 3.8 and 2.6% of the
FM and PFM variation, respectively, in our sample. Indivi-
duals carrying the GG genotype at rs312462 had a higher
TFM and PFM compared with GA carriers (P¼0.011 and
0.003, respectively). The contributions of rs312462 to the
phenotypic variation of TFM and PFM were 3.0 and 3.7%,
respectively. However, no significant association was found
between any SNP and the BMD, BMI or TLM variation in
young men (Table 5).
The associations among the peak BMD, obesity pheno-
types and SNPs in ALOX12 were analyzed using the QTDT for
our nuclear families. As the effects of parent phenotypes
were excluded in the analyses, all 400 families were included.
There were 284, 273, 195, 310 and 189 informative families
for the TDT analysis at rs2073438, rs2292350, rs312470,
rs434473 and rs312462, respectively. We did not detect
significant population stratification in our sample. The SNPs
rs2073438 and rs312462 were significantly associated with
the TFM and PFM in the total-association analysis (Po0.01).
For the within-family analysis, significant associations were
found between rs2073438 and the TFM, PFM and BMI
(P¼0.007, 0.012 and 0.038, respectively), whereas rs312462
showed only marginal association with the TFM (P¼0.049).
In the multiple parameters tests, permutations of 1000 tests
were performed. However, only rs2073438 retained signifi-
cant with-family associations with both the TFM and the
PFM (P¼0.033 and 0.015, respectively). Similar to the results
of the ANOVA, we failed to find significant associations
Table 5 Association of SNPs with phenotypic values in unrelated sons from single-offspring families (mean±s.d.)
Genotype n Lumbar spine
BMD (gcm
–2)
Femoral neck
BMD (gcm
–2)
Total hip
BMD (gcm
–2)
BMI
(kgm
–2)
TFM (kg) PFM (%) TLM (kg)
rs2073438
GG 173 1.140±0.142 1.002±0.137 1.018±0.137 23.5±3.5 15.06±6.83 20.90±7.01 51.15±5.32
AG 180 1.121±0.132 0.995±0.149 1.013±0.143 23.7±3.3 16.32±6.85 22.13±7.15 51.37±5.99
AA 47 1.184±0.136 0.983±0.137 1.019±0.124 24.1±3.1 18.37±6.93
# 24.46±6.67
## 50.96±5.33
P-value 0.076 0.579 0.696 0.597 0.001 0.015 0.918
rs2292350
GG 168 1.139±0.139 0.994±0.139 1.017±0.131 23.7±3.3 16.49±7.98 21.94±6.99 51.47±5.45
AG 183 1.140±0.133 1.000±0.148 1.020±0.149 23.8±3.5 16.06±7.11 21.99±7.38 51.06±5.86
AA 49 1.124±0.150 0.989±0.119 0.986±0.107 22.8±2.6 15.10±6.42 21.16±7.18 51.01±5.32
P-value 0.857 0.802 0.592 0.171 0.598 0.843 0.807
rs312470
AA 278 1.138±0.137 0.994±0.139 1.011±0.132 23.5±3.2 16.23±7.87 21.83±7.53 51.31±5.54
AG 111 1.146±0.139 1.003±0.149 1.026±0.150 23.9±3.6 16.14±6.41 22.18±6.36 51.06±5.82
GG 11 1.138±0.137 0.994±0.139 1.011±0.132 24.8±3.4 14.12±5.82 20.28±6.41 50.97±3.21
P-value 0.803 0.532 0.469 0.180 0.731 0.768 0.925
rs434473
AA 104 1.138±0.147 1.001±0.139 1.007±0.140 23.7±3.3 15.69±6.88 21.66±6.92 50.98±5.88
AG 210 1.135±0.132 0.999±0.144 1.016±0.136 23.6±3.3 15.85±6.85 21.74±7.22 51.25±5.55
GG 86 1.156±±0.138 0.987±0.144 1.014±0.138 23.8±3.6 17.45±9.19 22.57±7.42 51.47±5.57
P-value 0.560 0.519 0.535 0.874 0.203 0.608 0.822
rs312462
GG 287 1.145±0.140 0.998±0.145 1.016±0.139 23.9±3.3 16.93±7.61 22.67±7.01 51.06±5.71
GA 103 1.122±0.126 0.985±0.135 1.010±0.134 23.2±3.3 14.26±6.69* 19.62±7.01** 51.70±5.52
AA 10 1.123±0.178 1.107±0.117 1.161±0.139 22.1±3.8 13.54±6.88 24.10±4.36 50.51±3.21
P-value 0.234 0.254 0.144 0.632 0.003 0.001 0.570
Abbreviations: BMD, bone mineral density; BMI, body mass index; PFM, percentage fat mass; SNP, single-nucleotide polymorphism; TFM, total fat mass; TLM, total
lean mass. The P-values are the results of analysis of variance (ANOVA) tests for the least-square mean of the BMD among various genotypes after adjusting for the
significant covariates of age, weight and height. The P-values are the results of ANOVA tests for the least-square mean of the BMI, TFM and TLM among various
genotypes after adjusting for age as a significant covariate. Bold indicates significant P-values (Po0.05).
#P¼0.001, AA genotype versus GG genotype;
##P¼0.014,
AA genotype versus GG genotype; *P¼0.011, GG genotype versus GA genotype; **P ¼0.003, GG genotype versus GA genotype.
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tion tests) between any SNPs and the BMD at the lumbar
spine and hip, although rs2073438 was associated with
the femoral neck BMD in the total-population analysis
(P¼0.029) (Table 6).
Relationship of haplotypes and phenotypes
We conducted haplotype analyses using genotype data from
all five SNPs, and four common haplotypes accounted for
91.8% of the unrelated parents. We further evaluated the
association of haplotypes and the peak BMD with the obesity
phenotypes using the QTDT. There were 252, 246, 164 and
146 informative families for the TDT analysis at haplotype 1
(AGAGG), haplotype 2 (GAAAG), haplotype 3 (GGGAG)
and haplotype 4 (GGAGA), respectively. We failed to find
any evidence of population stratification for all haplotypes
(P40.05). For the total and within-family associations, a
significant association was found between the most common
haplotype (haplotype 1) and the TFM and PFM (both
Po0.05). Furthermore, haplotype 1 was still significantly
associated with the PFM after 1000 permutations (corrected
Pc¼0.033), but not with the TFM (corrected Pc¼0.092). The
results of the haplotype 1-association analysis are presented
in Table 7.
In addition, we also investigated the association between
haplotype 1 and the BMD and obesity phenotypes in 400
unrelated sons using GLM-ANOVA. The subjects carrying at
least one copy of haplotype 1 had a higher TFM and PFM
than non-carriers (P¼0.006 and 0.004, respectively). This
haplotype accounted for 2.5 and 2.7% of the variation in the
TFM and PFM, respectively, in this sample of younger males.
However, no significant association was found between
any haplotype and the BMI, TLM or peak BMD at any site
(data not shown).
Discussion
To the best of our knowledge, this is the first study to
investigate the possible influence of SNPs and haplotypes in
the ALOX12 gene on variations in obesity-related pheno-
types. Our results showed that the polymorphism rs2073438
of the ALOX12 gene is significantly associated with the TFM
and PFM, but not with the BMI or TLM in young men.
Furthermore, haplotype-based analyses supported this signi-
ficant association from the single-locus analyses. The SNP
rs2073438, with a polymorphism of G4T, is located in the
Table 6 P-values of tests for population stratification, total association and
within-family association using the QTDT.
rs2073438 rs2292350 rs312470 rs434473 rs312462
Tests of population stratification
Lumbar spine BMD 0.409 0.170 0.558 0.531 0.957
Femoral neck BMD 0.335 0.190 0.783 0.760 0.923
Total hip BMD 0.535 0.303 0.957 0.828 0.712
BMI 0.110 0.569 0.828 0.894 0.870
TFM 0.408 0.456 0.438 0.268 0.751
PFM 0.377 0.351 0.457 0.135 0.421
TLM 0.989 0.206 0.817 0.349 0.471
Test of total association
Lumbar spine BMD 0.683 0.738 0.554 0.542 0.501
Femoral neck BMD 0.029 0.172 0.279 0.081 0.655
Total hip BMD 0.420 0.851 0.405 0.915 0.276
BMI 0.146 0.669 0.289 0.369 0.929
TFM 0.002 0.434 0.942 0.472 0.0012
PFM 0.007 0.668 0.758 0.744 0.001
TLM 0.331 0.405 0.853 0.977 0.284
Test of within-family association
Lumbar spine BMD 0.359 0.293 0.845 0.399 0.814
Femoral neck BMD 0.826 0.585 0.479 0.585 0.909
Total hip BMD 0.892 0.411 0.700 0.809 0.844
BMI 0.038 0.489 0.781 0.624 0.907
TFM 0.007 0.283 0.608 0.192 0.049
PFM 0.012 0.323 0.755 0.184 0.117
TLM 0.492 0.669 0.766 0.474 0.846
P-value of 1000 permutations of the within-family association
Lumbar spine BMD 0.344 0.267 0.812 0.365 0.770
Femoral neck BMD 0.830 0.628 0.457 0.610 0.925
Total hip BMD 0.887 0.446 0.705 0.832 0.801
BMI 0.122 0.599 0.838 0.692 0.927
TFM 0.033 0.385 0.673 0.294 0.126
PFM 0.015 0.312 0.754 0.163 0.125
TLM 0.153 0.696 0.793 0.531 0.854
Abbreviations: BMD, bone mineral density; BMI, body mass index; PFM,
percentage fat mass; QTDT, quantitative transmission disequilibrium test;
TFM, total fat mass; TLM, total lean mass. The BMD values are adjusted for
age, height and weight. The BMI, TFM and TLM values are adjusted for age.
Bold indicates significant P-values (Po0.05).
Table 7 The QTDT results for the associations between haplotype 1 and phenotypic variations
Haplotype 1 (AGAGG) Test of population
stratification
Test of total
association
Test of within-family
association
P-value of 1000 permutations
of the within-family association
Lumbar spine BMD 0.508 0.853 0.502 0.456
Femoral neck BMD 0.347 0.019 0.835 0.840
Total hip BMD 0.630 0.353 0.909 0.912
BMI 0.848 0.431 0.856 0.853
TFM 0.892 0.0001 0.021 0.092
PFM 0.721 0.003 0.034 0.033
TLM 0.284 0.632 0.256 0.275
Abbreviations: BMD, bone mineral density; BMI, body mass index; PFM, percentage fat mass; QTDT, quantitative transmission disequilibrium test; TFM, total fat
mass; TLM, total lean mass. The BMD values are adjusted for age, height and weight. The BMI, TFM and TLM values are adjusted for age. Bold indicates significant
P-values (Po0.05).
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International Journal of Obesityintron1/exon2 boundary of ALOX12, only 639 base pairs
from the 50 promoter region. Moreover, based on the
information from HapMap, the criterion for tagging was
set at r
2 40.5, and rs2073438 as a tagging SNP captured
seven additional SNPs. Therefore, the significant association
of rs2073438 with the TFM and PFM suggests that the SNP
itself or the region around it may be important for
transcription initiation efficiency or may be in strong LD
with certain functional variants influencing the expression
of the ALOX12 protein. Further study is needed to clarify
how this intronic SNP affects protein function. Although
significant associations were observed between rs312462 and
the TFM and PFM using ANOVA, we failed to find significant
results in our QTDT analyses (both within-family and
1000-permutation tests). As the QTDT analysis is free of
confounding population-substructure effects compared
with the traditional-association approach, the results of our
study should be more valuable because of the robustness
of the TDT approach.
28 A possible reason for our result is
that the heterozygosity of rs312462 is relatively low, and the
statistical power of a family-based-association study depends
directly on the degree of allelic heterozygosity.
29
Interestingly, we found a significant association between
rs2073438 and the TFM, but not the BMI. The BMI has been
widely used as a surrogate phenotype for the assessment of
obesity status. However, the BMI alone may not accurately
reflect the percentage of body fat and the relative contribu-
tions of muscle and fat,
30 and as an index of body fatness,
BMI is significantly influenced by age and sex.
31 The subjects
of this study were healthy young men aged 20–40 years.
The TLM in our sample accounted for B70% of the body
mass; we speculate that the BMI in this study may be
skewed by the TLM so that the BMI values of these young
Chinese men do not accurately reflect body fat mass. Our
results are in accordance with the study of Liu et al.,
32 in
which the polymorphisms of the MTHFR gene were signi-
ficantly associated with the BMI; however, the association
diminished after adjusting for the LM. Therefore, the FM as
measured by DXA is a more refined measure of obesity.
ALOX12 belongs to the lipoxygenase superfamily, which
catalyzes the insertion of molecular oxygen into polyunsa-
turated fatty acids. It has become increasingly clear that
polyunsaturated fatty acids have an important function in
the control of adipogenesis and reduce the expression of
many enzymes involved in lipid metabolism.
33,34 Although
the exact mechanisms by which polyunsaturated fatty
acids exert their effects are not completely understood,
several transcription factors and nuclear receptors have been
identified as critical regulators of several important genes of
lipid metabolism. PPARG, a nuclear transcription factor, is
a dominant regulator of adipocyte-specific genes contributing
to adipocyte differentiation, susceptibility to obesity and
insulin sensitivity.
35,36 The substrates of ALOX12 (arachidonic
acids) and the products of the lipoxygenase reaction are both
effective PPARG activators, and ligand activation of PPARg
promotes the differentiation of mesenchymal stem cells into
adipocytes. Studies have shown that ALOX12 has an important
function in obesity-related diseases, such as hypertension,
diabetes and atherosclerosis.
22–24 More recently, Mehrabian
et al.
37 showed that ALOX5, another member of the lipoxy-
genase superfamily, has pleiotropic effects on adiposity and
type 2 diabetes-related traits. Our results, taken together with
the above studies, suggest the involvement of SNP rs2073438
and the AGAGG haplotype in ALOX12 in the variation of
obesity, perhaps through a PPARG-dependent pathway.
To date, 4200 different candidate genes have been asso-
ciated with obesity-related phenotypes,
38 and most of those
genes regulate the energy balance through the complex
central nervous system.
39 The mRNA and protein of ALOX12
has been described mainly in neurons and also in some
glial cells throughout the cerebrum, basal ganglia and
hippocampus.
40,41 Recently, Pratico et al.
42 showed that the
protein levels and activity of ALOX12 in affected frontal and
temporal regions of Alzheimer’s disease brains were signifi-
cantly increased. The levels of the metabolic products of
ALOX12 were also markedly elevated in cerebrospinal fluid
from mild cognitive impairment and Alzheimer’s disease
brains.
43 In these studies, they believed that ALOX12
metabolic pathway increased oxidative stress and inflamma-
tory responses, which is likely to have a more active function
in the pathogenesis of Alzheimer’s disease. Obesity was
determined as a state of chronic oxidative stress and
oxidative stress might be a major mechanism underlying
the development of obesity-related co-morbidities.
44,45 We
suspected that there may exist ALOX12 overexpression
in central nervous system similar to Alzheimer’s disease,
to affect the energy balance. However, all of the above are
just hypotheses and wait to be tested by further functional
analyses.
Polymorphism in ALOX12 has been associated with
the BMD in several independent studies. Xiong et al.
19
first performed an association analysis of 20 osteoporosis
candidate genes on the BMD variation at three clinically
important skeletal sites: the spine, hip and ultradistal
radius. Their findings show that ALOX12 is a suggestive
gene (0.01oPp0.05) for the BMD at the hip and ultradistal
radius in the total-population sample. However, the signi-
ficant association was mainly driven by the female subjects,
suggesting the possibility of a sex-specific association of
ALOX12 with the BMD. Extensive evidence suggests that the
loci that regulate the BMD do so in a sex-specific manner in
both human beings and experimental animals.
19,46 The sex
specificity of the associations between genes and the BMD
may involve the regulation of sex steroids. In addition,
Mullin et al.
20 also found that three SNPs from ALOX12 were
significantly associated with the BMD at the spine and hip in
postmenopausal Caucasian women. In this study, we studied
400 Chinese nuclear families with male offspring and used
TDT to simultaneously test the linkage and association
of ALOX12 gene polymorphisms with the peak BMD. No
significant within-family associations were found between
ALOX12 SNPs or haplotypes and the peak BMD in young
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21 showed
evidence of an association between the spine BMD and six
SNPs in the ALOX12 gene in both White men (aged 18–61
years) and women (aged 20–50 years). The conflicting results
may be due to the differences between the participants,
especially their ages, ethnicities or some other confounding
issue. This is the first study to investigate the possible
influence of ALOX12 SNPs and haplotypes on the BMD
variation in a non-Caucasian population. Therefore, our
results should be interpreted cautiously, and further studies
should be conducted to determine the strength of these
associations in various populations.
We also examined the relationship between the BMD and
the TFM and TLM in young men. Our results showed that
both the TFM and the TLM had significant positive
associations with the BMD, and the TLM was a stronger
predictor of the BMD than the TFM, consistent with previous
studies.
11,47 However, Cui et al.
10 reported that the LM was
the only independent factor contributing to the BMD, and
the FM was negatively related to the BMD in younger men.
In contrast, other independent studies have suggested that
the TFM has a stronger effect on the BMD in both pre- and
post-menopausal women.
48 The influence of body composi-
tion on the BMD may be confounded by gender, age,
menopausal status and other environmental factors.
49
Our study has several strengths. First, we chose all six
tagging SNPs of the ALOX12 gene. The extensive LD between
SNPs guaranteed that the entire gene had been tested for
an association with the BMD and obesity phenotypes.
Second, our sample was relatively large, composed of 1215
individuals from 400 nuclear families. Therefore, adequate
statistical power was ensured to find the genetic variants
of modest effect sizes. Third, we performed the QTDT and
1000-permutation analyses to avoid sample heterogeneity
and false-positive results because of multiple tests. Our study
has several limitations as well. Our nuclear families
contained few sibling pairs, and no linkage was detected in
this study. Environmental factors such as dietary fat intake
were not considered in this study.
In conclusion, we have shown that a genetic variation
(rs2073438 and haplotype AGAGG) in ALOX12 is associated
with the TFM in young Chinese men, but we failed to
observe a significant association between SNPs or haplotypes
and the peak BMD at any site. Our findings suggest that
ALOX12 is potentially important in the pathogenesis of
human obesity. Although the mechanisms underlying this
relationship are largely unknown, we speculate that ALOX12
may exert its effect on fat mass variation by activating the
PPARG pathway or affecting central nervous system to
regulate energy homeostasis.
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